Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2019
July 2019, Vol 9, No 7
July 2019, Vol 9, No 7
Decision Time Is Approaching for Practices in the Oncology Care Model
By
Stuart Staggs
Oncology Care Model
Since July 2016, more than 170 oncology practices across the United States have been participating in the Oncology Care Model (OCM), the Center for Medicare & Medicaid Innovation (CMMI)’s 5-year pilot program designed to deliver higher quality, more coordinated oncology care at the same or lower cost. When practices elected to participate in the OCM, they knew they would eventually have to decide whether to accept 2-sided risk or leave the program if a performance-based payment (PBP) was not achieved.
Read Article ›
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
By
Phoebe Starr
2019 ASCO Highlights
The FDA has announced the launch of an oncology-specific pilot program for physicians and patients who need access to investigational therapies. The expanded access pilot program is a concierge service, said Richard Pazdur, MD, Director, FDA’s Oncology Center of Excellence, who spoke at a press conference at the 2019 American Society of Clinical Oncology Annual Meeting.
Read Article ›
New Targeted Therapies for Metastatic Colorectal Cancer Recommended in the Updated NCCN Guideline
By
Wayne Kuznar
NCCN 2019 Conference Highlights
A growing number of targeted therapies and immunotherapies are now recommended in the updated National Comprehensive Cancer Network (NCCN) guideline for metastatic colorectal cancer (CRC). New first-line immunotherapy options for patients with mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) CRC are also listed in the new guideline.
Read Article ›
Revised Risk Categories in NCCN Guideline for Metastatic Renal-Cell Carcinoma Affects Preferred Front-Line Options
By
Wayne Kuznar
NCCN 2019 Conference Highlights
The updated guideline on the management of metastatic renal-cell carcinoma (RCC) from the National Comprehensive Cancer Network (NCCN), version 3.2019, underwent a major shift in its risk categories to define preferred and alternative first-line treatments.
Read Article ›
Oncology Reimbursement Reform: Changes on the Horizon
By
Chase Doyle
2019 ASCO Highlights
Formed 10 years ago with the Affordable Care Act, the Centers for Medicare & Medicaid Services (CMS) Center for Medicare & Medicaid Innovation (CMMI) has been tasked with developing new payment and delivery models designed to improve the efficiency of specialty care. Among those specialty models is the Oncology Care Model, which aims to improve cancer care delivery by providing higher quality, more coordinated care to Medicare beneficiaries at the same or lower cost than under traditional fee-for-service structures. At the 2019 American Society of Clinical Oncology Annual Meeting, Lara M. Strawbridge, MPH, Director, Division of Ambulatory Payment Models, Patient Care Models Group, CMMI, shared recent data from the model, which began in 2016 and is scheduled to run through the middle of 2021.
Read Article ›
Immunotherapy Moving into Earlier Lines of Lung Cancer Therapy
By
Wayne Kuznar
Immunotherapy
Moving PD-1 or PD-L1 inhibitors to an early line of therapy, immediately after chemoradiation, has improved survival for patients with unresectable, stage III non–small-cell lung cancer (NSCLC).
Read Article ›
Evolving Immuno-Oncology Strategies in Renal-Cell Carcinoma
By
Wayne Kuznar
Immunotherapy
The era of immunotherapy has opened new perspectives in renal-cell carcinoma (RCC), which is one of the tumors most highly infiltrated with CD T-cells and PD-1 expression, partially accounting for its sensitivity to immunotherapy. Other mechanisms to explain its sensitivity include myeloid infiltration, metabolic alterations, loss-of-function mutations, and human endogenous retroviruses.
Read Article ›
Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation
By
Phoebe Starr
AACR Highlights
Treatment with gilteritinib (Xospata) significantly improved overall survival (OS) with less toxicity compared with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and
FLT3
mutation, according to the final results of ADMIRAL, a phase 3 clinical trial presented at the 2019 American Association for Cancer Research meeting.
Read Article ›
High Tumor Mutation Burden Predictive Biomarker for Survival in Metastatic Lung Cancer
By
Phoebe Starr
AACR Highlights
Immune checkpoint inhibitors represent a tremendous advance in the treatment of several types of cancers. Although approximately 20% to 25% of patients will have durable responses with these agents, it has been challenging to find biomarkers to identify who these patients are.
Read Article ›
Infigratinib a Novel, Potent Selective TKI Targeting FGFR Fusions in Different Tumor Types
By
Phoebe Starr
AACR Highlights
Preclinical and clinical data support the potential for the investigational novel tyrosine kinase inhibitor (TKI) infigratinib for the treatment of different
FGFR
-driven tumor types, according to Sameek Roychowdhury, MD, PhD, Associate Professor, Medical Oncology, the Ohio State University, Columbus, who presented a poster with the preclinical results at the 2019 American Association for Cancer Research (AACR) meeting.
Read Article ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
2023 Spotlight: Amgen
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes